This trial aims to evaluate the safety, tolerability and efficacy of hUC-MSC-sEV-002 nebulizer in patients with allergic rhinitis and asthma. It consists of two parts: β Single-center dose exploration (The Affiliated Hospital of Qingdao University): A 3+3 escalation design will test three doses (1Γ10βΈ, 1Γ10βΉ, 1Γ10ΒΉβ° particles/mL) to determine the maximum tolerated dose (MTD).Three subjects will be enrolled in each dose group. If no Dose-Limiting Toxicity (DLT) is observed among the 3 subjects, the study may proceed to the next dose exploration. If 1 out of the 3 subjects experiences DLT, an additional 3 subjects will be enrolled in the same dose group; the study may move to the next dose exploration only if no DLT is observed in these additional 3 subjects. If more than 1 out of the 3 subjects develops DLT, the previous dose group will be defined as the MTD. A total of at least 9 and at most 18 subjects will be recruited for this clinical trial. β‘ Multi-center case expansion: Participants will be randomized 2:1 to hUC-MSC-sEV-002 or placebo groups for efficacy comparison.Eligibility criteria: 18-60 years old; moderate-to-severe allergic rhinitis (ARIA guidelines) with positive inhaled allergen skin test; asthma diagnosed per GINA 2022; signed informed consent.Intervention: Nebulization once daily (5 times/week, 2 weeks, 10 doses total). Follow-up visits at baseline, Week 2, 4, 12, 24, including symptom scales, lung function tests, nasal endoscopy, nasal exhaled nitric oxide test, chest X-ray, blood tests, and electrocardiogram. The trial is approved by the Medical Ethics Committee of The Affiliated Hospital of Qingdao University (No. QYFYEC2025-192). Participants may withdraw anytime without affecting medical care. Study period: Aug 2025-Aug 2027. Sample size: 9-18 for Part 1; Part 2 size based on Part 1 results.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
Timeframe: At Week 24
Forced Expiratory Volume in One Second (FEV1)
Timeframe: At Week 24
Drug-related adverse reaction rate
Timeframe: In the short term after treatment (0-24 hours)οΌAt Week 2
Blood Pressure
Timeframe: At Week 2
Changes in routine blood test
Timeframe: At Week 2
Changes in routine urine test
Timeframe: At Week 2
Whether abnormal changes occurred in the ECG
Timeframe: At Week 2
Total Nasal Symptom Score (TNSS)
Timeframe: At Week 24
Visual Analog Scale (VAS)
Timeframe: At Week 24
Asthma Control Test (ACT)
Timeframe: At Week 24
Peak Expiratory Flow (PEF)
Timeframe: At Week 24
Heart Rate
Timeframe: At Week 2
Body Temperature
Timeframe: At Week 2
C-reactive protein (CRP)
Timeframe: At Week 2
Alanine aminotransferase (ALT)
Timeframe: At Week 2
Creatinine
Timeframe: At Week 2
IgG, IgA, IgM, C3 ,C4
Timeframe: At Week 2
Aspartate aminotransferase (AST)
Timeframe: At Week 2